Filing Flows › Comparisons › NRXP vs CBIO
NRX Pharmaceuticals vs Crescent Biopharma: NRXP and CBIO compared
NRX Pharmaceuticals is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $1.0M for Crescent Biopharma (Q1 2026).
Where the money goes: NRXP and CBIO
NRX Pharmaceuticals (NRXP) · Q2 2026
NRX Pharmaceuticals, Q2 2026: revenue $1.1M, operating margin -590.8%, net loss $16.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Crescent Biopharma (CBIO) · Q1 2026
Crescent Biopharma, Q1 2026: revenue $1.0M, net loss $23.3M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
| NRX Pharmaceuticals (NRXP) | Crescent Biopharma (CBIO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2026 |
| Revenue | $1.1M | $1.0M |
| Operating margin | -590.8% | n/m |
| Net earnings | −$16.5M | −$23.3M |
| Operating cash flow | −$8.9M | −$8.9M |
Where the revenue comes from
NRX Pharmaceuticals
- Therapy: $871K (79%)
- Procedures: $230K (21%)
Questions
Which is bigger, NRX Pharmaceuticals or Crescent Biopharma?
NRX Pharmaceuticals is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $1.0M for Crescent Biopharma (Q1 2026).
More: NRX Pharmaceuticals earnings · how NRX Pharmaceuticals makes money · Crescent Biopharma earnings · how Crescent Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Apr 29, 2026). Fiscal quarters can end on different dates. Not investment advice.